Literature DB >> 24371624

Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report.

Kathryn C Squires1, Saketh R Guntupalli1, Premal H Thaker1.   

Abstract

► Eptifibatide is associated with profound thrombocytopenia and thrombosis secondary to a HITT-like mechanism associated with drug-dependant antibodies. ► Caution with eptifibatide use is needed in those pre-disposed to hypercoaguability, particularly those with an underlying malignancy.

Entities:  

Keywords:  Integrilin; Neoplasm; Platelets; Thrombus

Year:  2012        PMID： 24371624      PMCID： PMC3860694          DOI： 10.1016/j.gynor.2012.03.002

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  10 in total

1.  Uterine carcinosarcomas: incidence and trends in management and survival.

Authors:  C D Arrastia; R G Fruchter; M Clark; M Maiman; J C Remy; M Macasaet; E J Gates; T Di Maio; T Marzec
Journal:  Gynecol Oncol       Date:  1997-04       Impact factor: 5.482

2.  Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial.

Authors:  Tullio Palmerini; George Dangas; Roxana Mehran; Adriano Caixeta; Philippe Généreux; Martin P Fahy; Ke Xu; Ecaterina Cristea; Alexandra J Lansky; Gregg W Stone
Journal:  Circ Cardiovasc Interv       Date:  2011-10-25       Impact factor: 6.546

3.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

4.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

5.  Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.

Authors:  Andreas Greinacher; Birgitt Fuerll; Heike Zinke; Bernd Müllejans; William Krüger; Noemi Michetti; Wolfgang Motz; Hansjörg Schwertz
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

6.  Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.

Authors:  Duk-Woo Park; Sung-Cheol Yun; Seung-Whan Lee; Young-Hak Kim; Cheol Whan Lee; Myeong-Ki Hong; Sang-Sig Cheong; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  JACC Cardiovasc Interv       Date:  2008-10       Impact factor: 11.195

7.  Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.

Authors:  Kimberly N Russell; Joseph G Schnabel; Richard P Rochetto; Matthew C Tanner
Journal:  Pharmacotherapy       Date:  2009-07       Impact factor: 4.705

8.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.

Authors:  K M Hodivala-Dilke; K P McHugh; D A Tsakiris; H Rayburn; D Crowley; M Ullman-Culleré; F P Ross; B S Coller; S Teitelbaum; R O Hynes
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

9.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Authors:  Cunji Gao; Brian Boylan; Dan Bougie; Joan C Gill; Jessica Birenbaum; Debra K Newman; Richard H Aster; Peter J Newman
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

10.  The roles of platelet GPIIb/IIIa and alphavbeta3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow.

Authors:  Yiyao Liu; Fenglong Zhao; Wentian Gu; Haishiu Yang; Quoquan Meng; Yunxiang Zhang; Hong Yang; Qi Duan
Journal:  J Biomed Biotechnol       Date:  2009-10-28
  10 in total
  1 in total

1.  Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction.

Authors:  Michael Weinreich; Dexter Mendoza; Thomas Pettei; Evelina Grayver
Journal:  Cardiol Res       Date:  2014-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.